The claim

““Ozempic (semaglutide) causes thyroid cancer in humans.””

Ozempic and related GLP-1 drugs carry a thyroid C-cell tumor warning based on rodent studies, but current human evidence has not established that they cause thyroid cancer in people.

The FDA boxed warning for semaglutide (Ozempic/Wegovy) and similar GLP‑1 receptor agonists is driven primarily by findings of thyroid C-cell tumors in rats and mice, not confirmed causation in humans. In people, these drugs are contraindicated for those with a personal/family history of medullary thyroid carcinoma (MTC) or MEN2, reflecting a precaution given the uncertainty. Large studies and meta-analyses have produced mixed signals—some observational analyses report small associations for certain thyroid cancer outcomes, while others do not—so a causal link in humans remains unproven. Viral posts often omit this context and present the rodent warning as definitive proof of human cancer causation, which overstates the evidence. If concerned, patients should discuss individual risk (especially MTC/MEN2 history) with a clinician rather than stopping medication abruptly.